Why the study?
Does TNF-alpha neutralizing antibody (cV1q) improve cardiac function and limit pathological changes in a transgenic mouse model of heart failure?
Population
Transgenic mice with cardiac-specific overexpression of TNF-alpha that develop congestive heart failure, and…
Comparison
TNF-alpha neutralizing antibody administered… vs Saline treatment.
Design
Preclinical
Follow-up
6 weeks (from 6 to 12 weeks of age)
Authors
Loading...
TNF-alpha neutralization merits further preclinical study in HF models; leaves open any clinical translation.
Does TNF-alpha neutralizing antibody (cV1q) improve cardiac function and limit pathological changes in a transgenic mouse model of heart failure?
Blockade of TNF-alpha bioactivity with a neutralizing antibody preserves cardiac function and limits cardiac dilation in a transgenic mouse model of heart failure.
Kadokami et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: